Clinical outlook for type-1 and FOXP3+ T regulatory cell-based therapy

Silvia Gregori; Laura Passerini; Maria Grazia Roncarolo

doi:10.3389/fimmu.2015.00593

Clinical outlook for type-1 and FOXP3⁺ T regulatory cell-based therapy

Silvia Gregori, Laura Passerini, Maria Grazia Roncarolo

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.

Original language	English
Article number	593
Journal	Frontiers in Immunology
Volume	6
Issue number	NOV
DOIs	https://doi.org/10.3389/fimmu.2015.00593
Publication status	Published - 2015

Keywords

FOXP3
Gene transfer
IL-10
T regulatory cells
T regulatory type 1 cells
Tolerance
Treg-based therapy

ASJC Scopus subject areas

Immunology
Immunology and Allergy

Access to Document

10.3389/fimmu.2015.00593

Cite this

@article{b910fbb8453c45949532ff85e7c03ed0,

title = "Clinical outlook for type-1 and FOXP3+ T regulatory cell-based therapy",

abstract = "T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.",

keywords = "FOXP3, Gene transfer, IL-10, T regulatory cells, T regulatory type 1 cells, Tolerance, Treg-based therapy",

author = "Silvia Gregori and Laura Passerini and Roncarolo, {Maria Grazia}",

year = "2015",

doi = "10.3389/fimmu.2015.00593",

language = "English",

volume = "6",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

number = "NOV",

}

TY - JOUR

T1 - Clinical outlook for type-1 and FOXP3+ T regulatory cell-based therapy

AU - Gregori, Silvia

AU - Passerini, Laura

AU - Roncarolo, Maria Grazia

PY - 2015

Y1 - 2015

N2 - T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.

AB - T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.

KW - FOXP3

KW - Gene transfer

KW - IL-10

KW - T regulatory cells

KW - T regulatory type 1 cells

KW - Tolerance

KW - Treg-based therapy

UR - http://www.scopus.com/inward/record.url?scp=84949544239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949544239&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2015.00593

DO - 10.3389/fimmu.2015.00593

M3 - Article

AN - SCOPUS:84949544239

VL - 6

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - NOV

M1 - 593

ER -